BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yokoda R, Nagalo BM, Arora M, Egan JB, Bogenberger JM, DeLeon TT, Zhou Y, Ahn DH, Borad MJ. Oncolytic virotherapy in upper gastrointestinal tract cancers. Oncolytic Virother. 2017;7:13-24. [PMID: 29616200 DOI: 10.2147/ov.s161397] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Harryvan TJ, Golo M, Dam N, Schoonderwoerd MJA, Farshadi EA, Hornsveld M, Hoeben RC, Hawinkels LJAC, Kemp V. Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus. Cancer Gene Ther. [DOI: 10.1038/s41417-022-00507-9] [Reference Citation Analysis]
2 Yajima S, Sugawara K, Iwai M, Tanaka M, Seto Y, Todo T. Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma. Mol Ther Oncolytics 2021;23:402-11. [PMID: 34853811 DOI: 10.1016/j.omto.2021.10.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Galanopoulos M, Doukatas A, Gkeros F, Viazis N, Liatsos C. Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy. World J Gastroenterol 2021; 27(24): 3568-3580 [PMID: 34239270 DOI: 10.3748/wjg.v27.i24.3568] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Kubota Y, Kawazoe A, Shitara K. Perspective on the Immunotherapy of Gastric Cancer. Cancer Immunotherapy 2021. [DOI: 10.1007/13905_2021_5] [Reference Citation Analysis]
5 Haller SD, Monaco ML, Essani K. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer. Viruses. 2020;12. [PMID: 33213031 DOI: 10.3390/v12111318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Song X, Qi W, Guo J, Sun L, Ding A, Zhao G, Li H, Qiu W, Lv J. Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress. Oncol Lett 2020;20:46. [PMID: 32802168 DOI: 10.3892/ol.2020.11905] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
7 Niedźwiedzka-Rystwej P, Grywalska E, Hrynkiewicz R, Wołącewicz M, Becht R, Roliński J. The Double-Edged Sword Role of Viruses in Gastric Cancer.Cancers (Basel). 2020;12. [PMID: 32599870 DOI: 10.3390/cancers12061680] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Sugawara K, Iwai M, Yajima S, Tanaka M, Yanagihara K, Seto Y, Todo T. Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer. Mol Ther Oncolytics 2020;17:205-15. [PMID: 32346610 DOI: 10.1016/j.omto.2020.03.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]